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Methionine-restricted diet inhibits growth
of MCF10AT1-derived mammary tumors by
increasing cell cycle inhibitors in athymic
nude mice
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Abstract
Background: Dietary methionine restriction (MR) improves healthspan in part by reducing adiposity and by
increasing insulin sensitivity in rodent models. The purpose of this study was to determine whether MR inhibits
tumor progression in breast cancer xenograft model and breast cancer cell lines.
Methods: Athymic nude mice were injected with MCF10AT1 cells in Matrigel® and fed a diet containing either 0.
86 % methionine (control fed, CF), or 0.12 % methionine (MR) for 12 weeks. Plasma amino acid concentrations were
measured by UPLC, and proliferation and apoptosis were examined using RT-PCR, immunohistochemistry, and Cell
Titer 96® Aqueous One Solution Cell Proliferation assay.
Results: Mice on the MR diet had reduced body weight and decreased adiposity. They also had smaller tumors
when compared to the mice bearing tumors on the CF diet. Plasma concentrations of the sulfur amino acids
(methionine, cysteine, and taurine) were reduced, whereas ornithine, serine, and glutamate acid were increased in
mice on the MR diet. MR mice exhibited decreased proliferation and increased apoptosis in cells that comprise the
mammary glands and tumors of mice. Elevated expression of P21 occurred in both MCF10AT1-derived tumor tissue
and endogenously in mammary gland tissue of MR mice. Breast cancer cell lines MCF10A and MDA-MB-231 grown
in methionine-restricted cysteine-depleted media for 24 h also up-regulated P21 and P27 gene expression, and
MDA-MB-231 cells had decreased proliferation.
Conclusion: MR hinders cancer progression by increasing cell cycle inhibitors that halt cell cycle progression. The
application of MR in a clinical setting may provide a delay in the progression of cancer, which would provide more
time for conventional cancer therapies to be effective.
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Background
One of the most common cancers worldwide is breast
cancer, and it is the second leading cause of mortality in
women from the United States [1, 2]. Although conven-
tional therapies and surgical approaches have been de-
veloped, none are completely effective in removing and
annihilating the cancer.
Cancer cells alter their metabolic machinery to main-
tain a high level of metabolism and prevent the deple-
tion of a host of substrates, such as glucose and amino
acids that are used for energy. A significant aspect of
this reprogramming involves changes in the glycolytic
pathway, referred to as the Warburg effect [3, 4]. These
changes include an increase in pyruvate that is generated
via the glycolytic pathway. Pyruvate is converted to lactic
acid instead of acetyl-CoA which enters the TCA cycle
and ultimately forms citrate. In addition to metabolic
changes from Warburg effect, some cancers depend on
glutamate metabolism for fixing ammonia to acquire the
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nitrogen required for cellular growth [5]. Further, glu-
tamine synthetase is a target for activated β-catenin and
is regulated by the oncogene Myc [5], which connects
the metabolic regulation of cancer cells to several im-
portant growth and developmental signaling pathways.
Dietary nutritional control may be a feasible option for
supplementing cancer treatment. The use of caloric re-
striction (CR) is effective in inhibiting cancer develop-
ment in non-human primates and rodents [6, 7] and the
onset of age-related diseases [6]. However, recent evi-
dence suggests that CR can reduce function of the im-
mune system [8, 9], which may not be ideal for people
already fighting cancer. Further, the general population
is not in favor of reducing food consumption as required
by CR. A viable alternative to CR may be to restrict the
intake of dietary methionine.
Methionine is an essential amino acid with a multitude
of functions. It is prominent in protein translation, since
it is the N-terminal amino acid of most mammalian
proteins. Methionine is a precursor of glutathione, a tri-
peptide that reduces reactive oxygen species (ROS) and
protects cells from oxidative stress. Methionine is
needed for polyamine synthesis, in which polyamines
function during nuclear and cell division. Moreover, me-
thionine is a precursor of S-adenosyl methionine the
major source of methyl groups needed for methylation
of DNA, proteins and low Mr biomolecules/metabolites.
In rodents, a diet low in methionine (20-35 % of regular
chow) reduced adiposity in the fat depots and reduced
blood levels of lipids, glucose, IGF-1, and leptin, while
elevating levels of FGF21 and adiponectin [10–15]. Re-
duction in mitochondrial free radical production and
oxidative stress also occurs during MR in organs, such
as, liver, heart, and brain [16–18]. Finally, MR in rodents
promotes longevity and delays onset of age-related im-
pairments and chronic diseases [10, 19–21].
In intestinal, colon, and prostate cancer models, me-
thionine levels were restricted or excluded from diets to
examine the effects on tumor progression. In an intes-
tinal tumorigenesis model with Apc(Min/+) mice, folate
deficiency in combination with depletion of choline, me-
thionine, and vitamin B12 resulted in reduced tumor
size in mice treated by 5 weeks of age, but produced no
difference when started at 10 weeks of age [22].
Azoxymethane-treated rats when fed MR diet had a sig-
nificant reduction in formation of aberrant crypt foci in
colon, suggesting an inhibition of cell proliferation [21].
More recently, dietary MR in TRAMP mouse model
demonstrated a decrease in prostatic intraepithelial neo-
plasia with a concomitant drop in plasma IGF-1 levels
and reduced proliferation in prostate lobe-specific man-
ner [23]. In human prostate cancer cell lines grown in
the absence of methionine, the expression of cell cycle
inhibitors P21 and P27 increased and were identified as
a possible mechanism for halting the cell cycle and in-
creasing apoptosis [24]. These studies suggest that me-
thionine depletion in human prostate cells can inhibit
proliferation either by halting the cell cycle at the G1/S
checkpoint or by directing cells to go through apoptosis.
However, little is known about how MR alters the cell
cycle in other cancers, such as breast cancer. The
present study uses a xenograft model for breast cancer,
an immortalized human breast cell line, and an invasive
breast cancer cell line to examine whether MR alters cell
cycle inhibitors that could inhibit tumor progression.
Methods
Xenograft model for testing efficacy of methionine
restriction
MCF10AT1, human transformed breast cells, were a gift
obtained from Steven Santner at Barbara Ann Karmanos
Cancer Institute, Detroit, MI. The cells were maintained
in DMEM/F12 (Invitrogen, Carlsbad, CA) with 5 %
horse serum, 0.029 M sodium bicarbonate, and 10 mM
HEPES, and supplemented with insulin (10 μg/ml), EGF
(20 ng/ml), hydrocortisone (0.5 μg/ml), cholera toxin
(100 ng/ml), and 1 % penicillin-streptomycin solution.
Cells were routinely passaged weekly and maintained in
5 % CO2 at 37 °C.
The procedures and treatments used on the athymic nude
mice were reviewed and approved by Penn State College of
Medicine Institutional Animal Care and Use Committee
(IACUC#2012-082), and followed standard procedures
described in Guide for the Care and Use of Laboratory
Animals, 8th edition from the National Research Council. A
completed ARRIVE guidelines checklist is included in Add-
itional file 1. A total of ten million MCF10AT1 cells with
matrigel (1:1 (v/v), BD Biosciences, San Jose, CA) were
injected subcutaneously into the left flank region near the
mammary fat pad of each of 40 female athymic nude mice
(Strain-088 homozygous; 8 weeks of age; Charles River,
Wilmington, MA). The mice were fed sterile standard ro-
dent diet for 1 week after cell implantation. These mice
were divided into 2 feeding groups: (a) 20 mice on a sterile,
a chemically-defined AIN-76-based diet containing 0.86 %
methionine (control-fed diet; CF); and (b) 20 mice on a ster-
ile chemically-defined AIN-76-based diet containing 0.12 %
methionine (methionine-restricted diet; MR). The mice
were housed in groups of five and maintained on a 12 h
light-dark cycle and fed these diets ad libitum for 12 weeks.
Body weights and average diet intake for each group were
measured weekly.
At the end of the study, unfasted mice were eutha-
nized using CO2; whole blood was collected by cardiac
puncture, centrifuged, and plasma was collected and
stored at −80 °C for analysis. Plasma samples were ana-
lyzed for amino acid content, insulin, IGF-1, FGF21, lep-
tin, adiponectin, cholesterol, triglycerides, and glucose.
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Tumors were excised, weighed, and measured prior
to fixing in 10 % neutral buffered formalin (NBF).
Tumor volumes were determined using the formula:
0.523 x a2 x b, where a is the smallest diameter and b is
the largest. The fixed tumors were paraffin-embedded,
sectioned and stained for hematoxylin & eosin. Histopath-
ology analysis was performed by Dr Timothy Cooper
(Penn State College of Medicine), and the percent of
lesions morphologically resembling mild, moderate, or
florid intraductal papillomas (IDPs); ductal carcinoma in
situ (DCIS); or invasive carcinoma were calculated. The
tumor sections also were used for immunohistochemical
analysis of proliferation and apoptosis for all groups. Add-
itionally, the mammary glands from 10 mice of each group
were fixed in NBF for histology. At sacrifice, organ weights
for liver, kidneys, spleen, mammary fat pads, and left
gastrocnemius muscle were recorded.
Tumor cell proliferation and apoptosis
The percentages of Ki67 and cleaved caspase-3 positive
cells counted in triplicate under a high power field
(400X) were used as a measure of proliferation and
apoptosis, respectively. Briefly, formalin-fixed paraffin-
embedded mammary and MCF10AT1 tumor sections
were hydrated, subjected to antigen retrieval, and incu-
bated at room temperature with 1:100 anti-Ki67 antibody
(M7240, Dako North America Inc, Carpinteria, CA) for
30 min and 1:100 cleaved-caspase-3 antibody (9661, Cell
Signaling, Danvers, MA) for 1 h. Slides were developed
using the Dako Envision™ +/HRP Polymer detection sys-
tem (K4001, Dako North America Inc, Carpinteria, CA)
and visualized with 3,3'-Diaminobenzidine (DAB) chroma-
gen followed by hematoxylin counterstain. Staining was
completed using a Dako Autostainer Plus.
Amino acid analysis
Plasma amino acid concentrations were measured using
the Acquity UPLC (Waters Corporation, Milford, MA)
with the AccQ.Tag Ultra derivatization Kit (Waters
Corporation, Milford, MA). Plasma samples were depro-
teinized with a solution of 10 % sulfosalicylic acid and
250 pmol/μl of norvaline was used as the internal
standard.
Assays on plasma parameters
Enzyme-linked immunosorbent assay (ELISA) kits were
used to measure insulin (ALPCO Diagnostics, Salem, NH),
leptin, IGF-1, adiponectin (R&D Systems, Minneapolis,
MN), and FGF21 (Millipore Corp., Billerica, MA).
Colorimetric assays were used to determine plasma
triglycerides (TG) and total cholesterol (TC) (Thermo
Electron Corp. Beverly, MA). Blood glucose was mea-
sured using an AbbottH Freestyle glucometer and
glucose test strips.
Methionine restriction in cell culture
MDA-MB-231 and MCF10A cells were obtained from
American Type Culture Collection (Manassas, VA).
MDA-MB-231 cells were maintained in DMEM/F12
media with 10 % fetal bovine serum, and MCF10A cells
were maintained in DMEM/F12 media containing 5 %
horse serum with the addition of EGF (20 ng/ml), hydro-
cortisone (0.5 μg/ml), cholera toxin (100 ng/ml), and in-
sulin (10 μg/ml). Cells were routinely passaged weekly
and maintained in 5 % CO2 at 37 °C. Methionine re-
stricted media were specially formulated without me-
thionine, cysteine, and cystine (Life Technologies, Grand
Island, NY), and the FBS or horse serum was dialyzed in
PBS pH 7.2 three times over a period of 24 h at 4 °C
using a Slide-A-Lyzer™ dialysis flask with a 3.5 K
MWCO (Thermo Fisher Scientific, Waltham, MA) to re-
move all amino acids. Media were specially formulated
to be 80 % reduced in methionine from the regular
DMEM/F12 media (17.24 mg Met/L), with no cysteine
or cystine, but with all amino acids and non-essential
amino acids (methionine-restricted, cysteine-depleted
(MRCD) media). Cells were plated and grown to 80 %
confluence, washed once with PBS, and then given either
MRCD or regular DMEM/F12 media. Twenty-four
hours later, RNA was harvested from cells using Tri-
Reagent (Molecular Research Center, Cincinnati, OH),
according to the manufacturer’s instructions.
In vitro proliferation assay
Cells (MCF10A and MDA-MB-231) were plated with
40 μl of 1X105 cells/ml per well in a 96 well cell-
culture treated dish. The next day cells were washed
with PBS, and then treated with either MRCD or
regular DMEM/F12 media. At 0 and 24 h cells were
assayed for changes in proliferation by treating with the
Cell Titer 96® Aqueous One Solution Cell Proliferation
assay reagent, according to the manufacturer’s in-
structions (Promega, Madison, WI). Four experiments
with 6 replicates per treatment were conducted. Results
were analyzed using a 2-way ANOVA with Sidak’s com-
parison test.
Real-time PCR
RNA isolated from frozen tissue or cells from culture
was converted to cDNA using the Verso cDNA synthesis
kit (Thermo Fisher Scientific, Waltham, MA) according
to the manufacturer’s instructions. Primers were gener-
ated for HPRT, P21, P27, and cyclin D1 (Additional
file 1: Table S1). Real-time PCR was performed using
a SYBR-green GoTaq qPCR system (Promega, Madison
WI), with 40 cycles at 95 °C for 15 s, and then 60 °C for
1 min using Applied Biosystems StepOne Plus Real-Time
PCR System. Ct values were analyzed using the ΔΔ −Ct
method [25].
Hens et al. BMC Cancer  (2016) 16:349 Page 3 of 13
RNA isolation and RT-PCR from paraffin sections
Ten micron sections were obtained from the formalin-
fixed, paraffin-embedded MCF10AT1 tumors and mam-
mary fat pads of the athymic nude mice. Five sections
were collected in a microcentrifuge tube, and RNA was
isolated using miRCURY RNA isolation kit (Exiqon,
Woburn, MA) according to the manufacturer’s instruc-
tions. RNA (250 ng) was converted into cDNA for real-
time PCR analysis and analyzed as described above.
The Cancer Genome Atlas data analysis
The cBioPortal for Cancer Genomics (http://
www.cbioportal.org) was used to assess the changes
in P21 and P27 expression in breast cancer patients
from the Cancer Genome Atlas (TCGA) invasive breast
carcinoma cancer study (TCGA, Nature 2012) [26, 27].
This data set was screened for those patients containing
data on mRNA levels from Agilent microarrays. Data re-
trieved from the TCGA controlled-access database was
collected using tumors from patients who provided in-
formed consent according to guidelines laid out by the
TCGA Ethics, Law and Policy Group which is in compli-
ance with the Helsinki Declaration (http://www.wma.net/
en/30publications/10policies/b3/index.html).
Statistical analysis and data presentation
Histological analyses of mammary and tumor sections
from the nude mice were analyzed using an unpaired
Mann-Whitney one-tailed t-test to determine significance.
Ct values from RT-PCR results were analyzed unpaired
one-tailed t-test to determine significance. In vitro prolif-
eration assay data were analyzed using a 2-way ANOVA
with Sidak’s comparison test. All analyses were performed
using the statistical software package GraphPad PRISM
(GraphPad Software Inc, La Jolla, CA).
Results
Physiological changes
Physiological parameters of mice on CF and MR were
examined. Similar to previous studies [11], MR reduced
the body weight of mice, whereas percent weight of liver,
spleen, kidney, and mammary fat pad (MFP) were not
changed (Table 1). Muscle mass decreased in the mice
on MR diet. Future studies may provide a more in depth
understanding of the changes that were observed in the
muscle.
One of the hallmarks of cancer is increased metabolic
activity of the cells. Decreased plasma amino acid levels
in cancer patients supports the concept that the tumor
is parasitizing the organism and altering protein metab-
olism that would then affect the amino acid concentra-
tions [28]. In this study, increased levels of alanine,
glutamine, histidine, ornithine, and serine occurred in
the plasma, which may suggest that MR is maintaining
or improving the metabolic condition of the animals
(Table 2). Equally important is the finding that the
sulfur-containing amino acids (methionine, cysteine, and
taurine) were reduced significantly in plasma, providing
clear evidence that the MR diet reduces sulfur-
containing amino acids throughout the animal.
As predicted from previous studies of mice on a MR
diet [11, 29], reductions in plasma triglycerides, IGF1,
and glucose were observed (Fig. 1). Plasma levels of adi-
ponectin and FGF21 increased significantly in the MR
mice compared to the CF mice (Fig. 1), similar to what
was reported previously to occur in rodents on MR
[11, 13, 30]. Cholesterol levels were slightly elevated
in the MR mice. Leptin was not significantly changed
(Fig. 1), whereas leptin levels of C57BL/6 J mice on a
MR diet were reported to be lower [11]. These differ-
ences in leptin levels may be due to strain differences
between the two studies.
Methionine restriction inhibits tumor progression
The MCF10AT1 cell-derived tumors from mice on MR
diet were reduced in size when compared to the mice on
CF diet (Representative animals from MR and CF groups
in Fig. 2). Tumor weights averaged 20.2 ± 6.1 mg in mice
on the CF diet. The mice on the MR diet had a notable
decrease in tumor weight to 11.4 ± 4.0 mg that
Table 1 Physiological parameters of mice on MR and CF diets. A 2-tailed t-test was conducted
CF MR
Mean (g) SD Mean (%) SD N Mean SD Mean (%) SD N
Body weight 26.6 ±2.79 18 23.9 ±2.3*** 20
Liver 1.13 ±0.15 4.35 ±0.43 19 0.988 ±0.13** 4.15 ±0.49 20
Spleen 0.102 ±0.02 0.383 ±0.07 19 0.104 ±0.15 0.436 ±0.59 20
MFP (both) 0.271 ±0.06 1.01 ±0.20 18 0.275 ±0.10 1.13 ±0.35 20
Kidney (both) 0.343 ±0.04 1.33 ±0.19 19 0.303 ±0.05** 1.27 ±0.19 20
Muscle-left side 0.123 ±0.02 0.475 ±0.89 19 0.081 ±0.03**** 0.339 ±0.15** 20
Tumor-wt (mg) 20.2 ±6.1a 0.079 ±0.30 15 11.4 ±4 03a**** 0.049 ±0.02*** 20
****p ≤ 0.0001, ***p ≤ 0.001, **p ≤ 0.01
atumor is in mg not g
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corresponds to a reduction of 55 % (p ≤ 0.0001) in MR
mice when compared to the CF mice (Table 1). Descrip-
tive characteristics of the tumors indicated that the mice
on the MR diet trended to have fewer florid IDPs
(Table 3). There were no significant differences in mild
or moderate IDPs, but there was a significant difference
in the number of DCIS lesions between the two groups
(Table 3). This suggests that lesions formed prior to the
initiation of the MR diet were not eliminated by MR,
but that MR slowed tumor progression and reduced the
size of tumors formed by the implanted MCF10AT1
cells. The fact that there was a population of mice that
acquired an invasive carcinoma phenotype suggests that
some cells may be able to escape the MR inhibition
through an unknown mechanism.
Methionine restriction decreases proliferation while
increasing apoptosis
To understand a possible mechanism for the decreased
tumor size in the mice on the MR diet, proliferation and
apoptosis were examined. Histological sections of the
both tumor and nearby mammary tissue were stained
for Ki67, a marker for proliferation. A total of 20 animals
per treatment were examined for levels of Ki67 staining.
Representative images demonstrate that the number of
Ki67-positive stained cells was reduced in the tissue
from mice on the MR diet (Fig. 3a and c). The number
of proliferating cells in the tumor tissue was 13.8 ± 0.8 %
cells in CF mice, while 11.6 ± 1.1 % cells in MR mice
(Fig. 3e; p < 0.05). Consecutive sections of tumor tissue
were stained for activated caspase-3, as an indicator of
apoptosis (Fig. 3b and d); MR mice had significantly ele-
vated levels of activated caspase-3 (MR: 3.82 ± 0.66 %
cells, p < 0.05), compared with CF mice (CF: 2.44 ± 0.30 %
cells) (Fig. 3f).
Changes in cell cycle regulators by methionine restriction
The decrease in proliferation combined with the in-
crease in apoptosis suggests that MR may perturb the
cell cycle. To investigate this possibility, RNA was har-
vested from frozen mammary tissue obtained from CF-
and MR-treated nude mice. Expression of murine cell
cycle inhibitors P21 and P27 and the cell cycle regulator
cyclin D1 were measured by real-time PCR in the nude
mice. Although there was a slight decrease in cyclin D1,
this effect was not significant (Fig. 3a). P21 expression
was significantly increased (Fig. 4b, p ≤ 0.01) in the
mammary gland of MR mice, while P27 was not affected
(Fig. 4c). To determine whether the human cell-derived
tumors were affected similarly by MR, paraffin sections
of embedded tumors from CF or MR mice were col-
lected, and RNA was isolated. Real-time PCR using
primers specific to human P21 and P27 were examined.
There was a trend indicating that human P21 was
increased in the tumors from MR fed mice (Fig. 4d,
p = 0.09), and a slight decrease in P27 (Fig. 4e, p ≤ 0.05).
To determine whether the changes in cell cycle con-
trol could occur in other breast cancer cells, breast can-
cer cell line MDA-MB-231 and MCF10A immortal cells
were examined under conditions of MR. Cells were
grown in regular media and plated at 70 % confluency.
The next day, media was changed to either regular
media (17.24 mg/L of methionine), or MRCD (3.45 mg/L
of methionine) media. Cells were harvested for RNA ex-
traction after 24 h. Real time PCR revealed in both
MCF10A and MDA-MB-231 cells that P21 (p ≤ 0.001)
and P27 (MCF10A p ≤ 0.01, MDA-MB-231 p ≤ 0.05) were
significantly increased by MR (Fig. 4f-i). This suggests that
the MR effect on the cell cycle inhibitors may be a similar
response to MR in both breast cancer cells and immortal-
ized breast cells. Both MCF10A and MDA-MB-231 cells
were examined for changes in proliferation over 24 h
(Fig. 5). At 24 h, MDA-MB-231 had a significant reduc-
tion of proliferation (p ≤ 0.05) by diet, and was further af-
fected by the interaction of diet and time (p ≤ 0.001).
Proliferation in MCF10A cells was not initially affected by
MR, but there were differences in proliferation over time
(p = 0.0013). The differences in proliferation may indicate
Table 2 Plasma amino acid concentrations from mice on MR
and CF diets. Levels of methionine, cysteine, and taurine in the
plasma from mice on the MR diet are significantly lower than
those on the control diet. The Kruskal-Wallis test was used to
analyze the differences in amino acid concentration
CF MR
Mean (nmol/mL) SD N Mean (nmol/mL) SD N
Ala 398 ±85 17 520 ±122*** 18
Arg 133 ±29 17 117 ±21 18
Asp 11.8 ±4.9 16 10.3 ±3.1 18
Cys 4.39 ±2.4 13 2.22 ±0.44* 9
Gln 622 ±89 17 812 ±106**** 18
Glu 106 ±20 17 117 ±19 18
His 88.8 ±11 17 112 ±20*** 18
Ile 94.8 ±32 17 108 ±27 18
Leu 139 ±47 17 180 ±46** 18
Met 248 ±125 17 46.9 ±17**** 18
Orn 62.7 ±29 17 114 ±41*** 18
Phe 114 ±42 17 132 ±39 18
Pro 69.5 ±8.6 17 82.4 ±34 18
Ser 218 ±34 17 339 ±84**** 18
Tau 226 ±50 17 77.1 ±35**** 18
Thr 346 ±94 17 383 ±136 18
Tyr 89.5 ±19 17 107 ±28* 18
Trp 130 ±29 17 128 ±29 18
****p ≤ 0.0001, ***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05
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that MR may be more effective at hindering invasive
breast cancer cells.
To further examine the connection of P21 and P27 ex-
pression in breast cancer, patients from the Cancer Gen-
ome Atlas (TCGA) invasive breast carcinoma cancer
study were examined to determine whether expressions
of Cdkn1a (P21) and Cdkn1b (P27) genes were inhibited
in breast cancer tumors (TCGA, Nature 2012) [26, 27].
This data set contains 825 patients, of which data are
available for 526 patients regarding mRNA expression
levels from Agilent microarrays. Alterations in P21 or
P27 expression occurred in 10 % of the 526 patients. Of
Fig. 1 Selected analytes measured in the plasma from nude mice on MR or CF diet. A 2-tailed t-test with Welch’s correction for unequal variance
was conducted. **** p≤ 0.0001, *** p≤ 0.001, ** p≤ 0.01, * p ≤ 0.05
Fig. 2 Representative MCF10AT1 breast tumors (black circles left-flank) in CF and MR fed nude mice at termination. Left mammary gland (#4) is
indicated with arrows
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those 52 patients, 56 % had decreases in P21, P27, or
both. Four patients had decreases in both P21 and P27,
11 patients had decreases in P21, and 14 patients had
decreases in P27. Of the 52 patients, information was
available regarding human epidermal growth factor re-
ceptor 2 (Her2), estrogen receptor (ER), and progester-
one receptor (PR) status in 32 patients. Interestingly,
45 % of patients with decreased expression of P21 were
Her2, ER, and PR negative (Fig. 6a), and patients with
lower levels of P21 or P27 had reduced survival times
following diagnosis (Fig. 6b). This may suggest that can-
cer patients following an MR diet may benefit, since in-
creased levels in P21 and P27 can inhibit the cancer cell
proliferation, providing a longer period of time for other
established cancer therapies to be effective.
Table 3 Characteristics of tumor lesions formed from MCF10AT1
cell implants in the nude mice. Classifications in order of tumor
progression included mild intraductal papilloma (IDP), moderate
IDP, florid IDP, ductal carcinoma in situ (DCIS), and invasive
carcinoma
Lesions CF MR
Mean (%) SD N Mean (%) SD N
Mild IDP 46.0 ± 19 15 49.4 ±15 18
Moderate IDP 24.7 ±13 15 26.7 ±11 18
Florid IDP 6.93 ±6.7 15 3.89 ±6 18
DCIS 1.07 ±2.8 15 0 ± 0 * 18
Invasive carcinoma 21.3 ±15 15 20.0 ±13 18
* p ≤ 0.05
Fig. 3 Increases in apoptosis and decreases in proliferation occur in mice on the MR diet when compared to mice on the CF diet. a, c are
representative images of Ki67 positive staining in mammary tissue near the tumor. b, d represent images of cleaved caspase-3 (CC3) positive
staining in the tissue. a, b are representative sections from mice on the MR diet and c, d are representative sections from mice on the CF diet.
e and f quantify the Ki67 and cleaved caspase-3 stained tissue sections from 20 animals per treatment, respectively. Mann-Whitney unpaired
one-tailed t-test was performed on the samples. * p≤ 0.05, ** p≤ 0.01
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Fig. 4 (See legend on next page.)
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(See figure on previous page.)
Fig. 4 Methionine restriction increases cell cycle inhibitors P21 and P27, while decreasing cyclin D1. a Murine cyclin D1 expression from
mammary tissue near the MCF10AT1 tumor in CF and MR mice. N = 5 CF, =3 MR. b Murine P21 expression from mammary tissue sampled near
tumor in nude mice on MR or CF diet. N = 9 CF, 7 = MR; c Expression of murine P27 from mammary tissue sampled near the tumor in nude mice
on MR and CF diet. N = 7 CF, 7 = MR. d Real-time PCR on MCF10AT1 tumor from paraffin sections demonstrated a trend towards an increase in
human P21 expression. e Real-time PCR on MCF10AT1 tumor from paraffin sections demonstrated a decrease in human P27 expression in the
MCF10AT1 cells that comprise the human tumor (p = 0.09). D. and E. both had N = 5 animals each for CF and MR. f Increased P21 expression by
real-time PCR in the breast cancer cell line MCF10A after growing cells in in methionine-restricted cysteine-depleted (MRCD) media for 24 h.
g Increased P27 expression by real-time PCR in the breast cancer cell line MCF10A after growing cells in MRCD media for 24 h. h Increased
P21 expression by real-time PCR in the breast cancer cell line MDA-MB-231 after growing cells in MRCD media for 24 h. i Increased P27 expression by
real-time PCR in the breast cancer cell line MDA-MB-231 after growing cells in MRCD media for 24 h. f-i Cell culture experiments N = 4, with 3 replicates
in each experiment. Mann-Whitney unpaired one-tailed t-test., ***p≤ 0.001. ** p≤ 0.01, * p≤ 0.05
Fig. 5 Reduced levels of proliferation were seen by 24 h in MDA-MB-231 and to a lesser degree in MCF10A cells. In both cell types, time had
significant affect on proliferation. In MDA-MB-231 cells, time, diet, and the interaction of time and diet on proliferation were significantly affected
by MRCD media, whereas in MCF10A cells only an interaction with time and MR affected proliferation. Data was normalized to cells grown in regular
media at time 0 and analyzed using a two-way ANOVA with Sidak’s multiple comparisons. ****p≤ 0.0001, ***p≤ 0.001, ** p≤ 0.01, * p≤ 0.05
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Discussion
Dietary MR has been identified as a strategy for disease
prevention and increased lifespan in experimental ani-
mals [10, 19, 31, 32]. We hypothesize that MR may be
used as a potential strategy for inhibiting carcinogenesis,
and to test this hypothesis, we used the xenograft model
for breast cancer by injecting MCF10AT1 cells into nude
mice and examined the development tumors in these
mice for 12 weeks. Our findings support this hypothesis
and indicate that MR inhibits the growth of breast can-
cer tumors and induces apoptosis.
High levels of IGF1 and insulin in humans have been
linked to increased risk of breast cancer [33]. In carcino-
genesis, growth factors, such as IGF1 and insulin, stimu-
late growth and progression of cancer [34]. Therefore,
the reduction in plasma IGF1 and insulin by MR suggest
that the reduced levels in the insulin/IGF1 axis may in-
hibit tumor development in this xenograft model.
Methionine functions as the donor for the C2-C4
and amine nitrogen during the synthesis of the poly-
amines spermidine and spermine. Ornithine, the pre-
cursor of putrescine (which in turn is the precursor
of spermidine and spermine), is increased in mice on
the MR diet. Polyamines are involved in the regulation of
proliferation, growth, and survival of cells [35]. High levels
of polyamines have been identified in several cancers [36],
and the inhibition of polyamine synthesis has been shown
to have antitumor effects on skin, colon, and prostate
cancers [37, 38]. The increase in ornithine suggests an in-
hibition of polyamine production. The metabolism of
polyamines is strictly controlled and contains two rate-
limiting enzymes: ornithine decarboxylase and S-adenosyl
methionine decarboxylase [39]. Ornithine, spermidine,
and spermine were previously reported to be increased in
the liver of MR rats [29]. In the Perrone et al. 2012 study
[29], gene expression of the two rate-limiting enzymes of
polyamine synthesis in the liver were not inhibited. The
conflicting findings regarding polyamine synthesis suggest
that either MR effects on the tumor are independent of
polyamine synthesis, or alternatively, polyamine function
and synthesis are regulated differently in liver and mam-
mary gland.
Taurine is a sulfur-containing amino acid that contrib-
utes to cell volume homeostasis and affects apoptosis
mechanisms [40]. Taurine plasma levels are decreased in
mice on MR. In cancer, volume-sensitive taurine cor-
relates with cisplatin resistance [41]. Recently, taurine
has been shown to induce apoptosis through PUMA
Fig. 6 Patients from the TCGA Invasive Breast Carcinoma study [26, 27] with altered P21 and P27 had a tendency to be Her2 negative and had
decreased survival. a. Estrogen receptor (ER), progesterone receptor (PR), and ErbB2 receptor (Her2) status in the 11 patients with decreases in the
CDKN1a (P21) gene expression and ER, PR, and Her2 status of the 21 patients with decreases in the CDKN1b (P27) gene expression. b. Survival
curve of patients with decreases in cdkn1a or cdkn1b gene expression compared to the 526 breast invasive carcinoma patients with mRNA
Agilent microarray data. A rapid decrease in overall survival occurs in patients with decreases in cdnk1a or cdnk1b gene expression when
compared to all patients with cancer
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(p53- up regulated modulator of apoptosis) in human
colorectal, ovarian, and cervical cancer cells [41–43].
A decrease in taurine levels resulted in reduced cell
volume that induced levels of activated caspase-3,
which led to apoptosis in cervical adenocarcinoma
cells [44]. Therefore, the MR effects on blood taurine
levels (Table 2) could affect PUMA and lead to an in-
crease in apoptosis in the mammary gland tissue and
MCF10AT1 tumors of the MR mice, but this would
need to be confirmed in future studies. Taurine has
been examined as a novel tumor marker in female
breast cancer patients. A decrease in serum taurine
levels was observed in people with breast cancer or at
high risk of breast cancer. Further, an inverse correl-
ation between vascular endothelial growth factor
(VEGF,marker for angiogenesis) and taurine concen-
trations has been demonstrated [45]. Therefore, the
connection between taurine, MR, and cancer is con-
voluted and complicated, and further research is
needed to understand the implication of reduced
plasma levels of taurine in MR mice.
Conclusion
In both the xenograft model and in breast cancer cell
lines, the mechanism by which MR inhibits tumor pro-
gression appears to be a coordinated effort of inhibiting
the cell cycle by stimulating the cell cycle inhibitors, P21
and P27. In both the MCF10AT1 tumors and surround-
ing mouse mammary tissue levels of P21 expression
were elevated. Levels of P27 were not significantly chan-
ged in the xenograft model, suggesting that the effect of
MR is more related directly to inhibiting P21 than P27.
Both the metastatic breast cancer cell line (MDA-MB-
231) and the immortalized breast cell line (MCF10A)
responded to MR similarly to that seen in the xenograft
model further supporting the relevance of P21 induction.
In particular MDA-MB-231 cells had reduced cell prolif-
eration after 24 h in MRCD media. Additionally, P27
also was elevated in the breast cancer cell lines, suggest-
ing that it too may be involved in the suppression of
tumor progression. Further evidence of P21 and P27 im-
portance in patients with breast cancer was revealed in
the analysis of the TCGA Breast Carcinoma Cancer
study data set [26, 27]. Survival analysis revealed that pa-
tients with decreased P21 or P27 expression had reduced
survival. This suggests that, if MR increases P21 and/or
P27 expression, there may be an increased length of sur-
vival in breast cancer patients.
The results from the present study indicate that MR
may be a protective agent against cancer progression,
but does not completely inhibit cancer progression.
Therefore, the application of MR in a clinical setting
could be both safe and a feasible option for arresting the
progression of breast cancer while providing patients
with more time to be treated by conventional methods
to eradicate the cancer. Further studies are needed to
examine the effect of MR in combination with chemo-
therapeutic and immunotherapeutic treatments.
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